BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 8804334)

  • 1. Growth hormone treatment in osteogenesis imperfecta with quantitative defect of type I collagen synthesis.
    Antoniazzi F; Bertoldo F; Mottes M; Valli M; Sirpresi S; Zamboni G; Valentini R; Tató L
    J Pediatr; 1996 Sep; 129(3):432-9. PubMed ID: 8804334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Positive linear growth and bone responses to growth hormone treatment in children with types III and IV osteogenesis imperfecta: high predictive value of the carboxyterminal propeptide of type I procollagen.
    Marini JC; Hopkins E; Glorieux FH; Chrousos GP; Reynolds JC; Gundberg CM; Reing CM
    J Bone Miner Res; 2003 Feb; 18(2):237-43. PubMed ID: 12568401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of two years of growth hormone (GH) replacement therapy on bone metabolism and mineral density in childhood and adulthood onset GH deficient patients.
    Longobardi S; Di Rella F; Pivonello R; Di Somma C; Klain M; Maurelli L; Scarpa R; Colao A; Merola B; Lombardi G
    J Endocrinol Invest; 1999 May; 22(5):333-9. PubMed ID: 10401706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone mineral density and bone turnover before and after surgical cure of Cushing's syndrome.
    Hermus AR; Smals AG; Swinkels LM; Huysmans DA; Pieters GF; Sweep CF; Corstens FH; Kloppenborg PW
    J Clin Endocrinol Metab; 1995 Oct; 80(10):2859-65. PubMed ID: 7559865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of short- and long-term growth hormone treatment on bone mineral density and bone metabolism of prepubertal children with idiopathic short stature: a 3-year study.
    Lanes R; Gunczler P; Esaa S; Weisinger JR
    Clin Endocrinol (Oxf); 2002 Dec; 57(6):725-30. PubMed ID: 12460321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osteogenesis imperfecta: bone turnover, bone density, and ultrasound parameters.
    Cepollaro C; Gonnelli S; Pondrelli C; Montagnani A; Martini S; Bruni D; Gennari C
    Calcif Tissue Int; 1999 Aug; 65(2):129-32. PubMed ID: 10430645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced serum levels of carboxy-terminal propeptide of human type I procollagen in a family with type I-A osteogenesis imperfecta.
    Minisola S; Piccioni AL; Rosso R; Romagnoli E; Pacitti MT; Scarnecchia L; Mazzuoli G
    Metabolism; 1994 Oct; 43(10):1261-5. PubMed ID: 7934978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of 12 months of recombinant growth hormone therapy on parameters of bone metabolism and bone mineral density in patients on chronic hemodialysis.
    Kotzmann H; Riedl M; Pietschmann P; Schmidt A; Schuster E; Kreuzer S; Kainberger F; Frisch H; Geyer G; Hörl WH; Mayer G; Luger A
    J Nephrol; 2004; 17(1):87-94. PubMed ID: 15151263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative study of the changes in insulin-like growth factor-I, procollagen-III N-terminal extension peptide, bone Gla-protein, and bone mineral content in children with Turner's syndrome treated with recombinant growth hormone.
    Bergmann P; Valsamis J; Van Perborgh J; De Schepper J; Van Vliet G
    J Clin Endocrinol Metab; 1990 Dec; 71(6):1461-7. PubMed ID: 2229302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of prolonged growth hormone replacement on bone metabolism and bone mineral density in hypopituitary adults.
    Beshyah SA; Kyd P; Thomas E; Fairney A; Johnston DG
    Clin Endocrinol (Oxf); 1995 Mar; 42(3):249-54. PubMed ID: 7758229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of 12 months rec-GH therapy on bone and collagen turnover and bone mineral density in GH deficient children with thalassaemia major.
    Sartorio A; Conte G; Conti A; Masala A; Alagna S; Rovasio P; Faglia G
    J Endocrinol Invest; 2000 Jun; 23(6):356-61. PubMed ID: 10908162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone alkaline phosphatase and collagen markers as early predictors of height velocity response to growth-promoting treatments in short normal children.
    Crofton PM; Stirling HF; Schönau E; Kelnar CJ
    Clin Endocrinol (Oxf); 1996 Apr; 44(4):385-94. PubMed ID: 8706304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone mineral density and body composition before and during treatment with gonadotropin-releasing hormone agonist in children with central precocious and early puberty.
    Boot AM; De Muinck Keizer-Schrama S; Pols HA; Krenning EP; Drop SL
    J Clin Endocrinol Metab; 1998 Feb; 83(2):370-3. PubMed ID: 9467543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of growth hormone replacement therapy in hypopituitary adults on calcium and bone metabolism.
    Beshyah SA; Thomas E; Kyd P; Sharp P; Fairney A; Johnston DG
    Clin Endocrinol (Oxf); 1994 Mar; 40(3):383-91. PubMed ID: 8187303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in bone mass and serum markers of bone metabolism after parathyroidectomy.
    Thorsen K; Kristoffersson AO; Lorentzon RP
    Surgery; 1997 Nov; 122(5):882-7. PubMed ID: 9369887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of long-term treatment with growth hormone on bone and mineral metabolism in children with growth hormone deficiency.
    Saggese G; Baroncelli GI; Bertelloni S; Cinquanta L; Di Nero G
    J Pediatr; 1993 Jan; 122(1):37-45. PubMed ID: 8419613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mortality and morbidity in patients with osteogenesis imperfecta in Denmark.
    Folkestad L
    Dan Med J; 2018 Apr; 65(4):. PubMed ID: 29619932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of long-term growth-hormone substitution therapy on bone mineral density and parameters of bone metabolism in adult patients with growth hormone deficiency.
    Kotzmann H; Riedl M; Bernecker P; Clodi M; Kainberger F; Kaider A; Woloszczuk W; Luger A
    Calcif Tissue Int; 1998 Jan; 62(1):40-6. PubMed ID: 9405732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BPS804 Anti-Sclerostin Antibody in Adults With Moderate Osteogenesis Imperfecta: Results of a Randomized Phase 2a Trial.
    Glorieux FH; Devogelaer JP; Durigova M; Goemaere S; Hemsley S; Jakob F; Junker U; Ruckle J; Seefried L; Winkle PJ
    J Bone Miner Res; 2017 Jul; 32(7):1496-1504. PubMed ID: 28370407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment.
    Land C; Rauch F; Travers R; Glorieux FH
    Bone; 2007 Mar; 40(3):638-44. PubMed ID: 17127117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.